A novel GLP-1 receptor agonist reduced cardiovascular event risk by 27% and kidney disease progression by 32% compared with placebo for high-risk adults with type 2 diabetes, with or without background SGLT2 inhibitor therapy, data show. Hertzel C.
from Google Alert - health https://ift.tt/3y4wEF1
via IFTTT
0 comments:
Post a Comment